Clinical outcomes for patients with thymoma and thymic carcinoma after undergoing different front-line chemotherapy regimens

WEI-LI MACHIA-CHI LINFENG-MING HSUJANG-MING LEEJIN-SHING CHENYEN-LIN HUANGYIH-LEONG CHANGChang, Chin-HaoChin-HaoChangCHIH-HSIN YANG2022-08-032022-08-032022-03-292045-7634https://scholars.lib.ntu.edu.tw/handle/123456789/616144Front-line platinum-base chemotherapy for advanced thymoma and thymic carcinoma (TC) improves resectability and prolongs patients' overall survival (OS). In this study, we evaluated patients' outcomes given different front-line regimens: cisplatin, doxorubicin, and cyclophosphamide (CAP); cisplatin and etoposide (EP); or cisplatin and paclitaxel (TP).enfront-line chemotherapy; overall survival; thymic carcinoma; thymoma[SDGs]SDG1[SDGs]SDG3Clinical outcomes for patients with thymoma and thymic carcinoma after undergoing different front-line chemotherapy regimensjournal article10.1002/cam4.4711353483072-s2.0-85127229017WOS:000773998900001https://scholars.lib.ntu.edu.tw/handle/123456789/614535